Truist analyst Asthika Goonewardene downgraded Harpoon Therapeutics to Hold from Buy with a $2 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HARP:
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- HARP Stock Doubles after Positive Phase 1 Trial Data
- Biotech Alert: Searches spiking for these stocks today
- Harpoon presents interim results from Phase 1 evaluating single-agent HPN217
- Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma